Skip to content
OpenCapital
Get started

BioRestorative Therapies BRTX Q1 2026 earnings

Reported May 14, 2026 · Before market open

Revenue$23.2KMiss by $289.3K
EPS-$0.19Beat by $0.01
Revenue estimate$312.5K
EPS estimate-$0.20

Next report

Aug 11, 2026 (In 1 week)
Revenue estimate$600.0K
EPS estimate-$0.15

Versus estimates

Revenue

Q1 2026$23.2KMiss by $289.3K
Q4 2025$20.0KMiss by $130.0KQ3 2025$11.8KMiss by $448.2KQ2 2025$303.3KBeat by $103.3KQ1 2025$25.0KMiss by $355.0KQ4 2024$43.3KMiss by $431.7K

Diluted EPS

Q1 2026-$0.19Beat by $0.01
Q4 2025-$0.37In lineQ3 2025-$0.33Beat by $0.03Q2 2025-$0.30Beat by $0.11Q1 2025-$0.56Miss by $0.24Q4 2024-$0.20Beat by $0.07

Ask the moment BioRestorative Therapies reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did BioRestorative Therapies report Q1 2026 earnings?
BioRestorative Therapies (BRTX) reported Q1 2026 earnings on May 14, 2026 before market open.
What were BioRestorative Therapies's Q1 2026 revenue and EPS?
BioRestorative Therapies reported revenue of $23.2K and eps of $-0.19 for Q1 2026.
Did BioRestorative Therapies beat estimates in Q1 2026?
Revenue missed the consensus estimate of $312.5K by $289.3K. EPS beat the consensus estimate of $-0.20 by $0.01.
How did BioRestorative Therapies's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 7.3% from $25.0K a year earlier and eps grew 66.1% from $-0.56.
Where can I find BioRestorative Therapies's Q1 2026 SEC filings?
You can read the 10-Q periodic report (0001493152-26-023126) directly on SEC EDGAR. The filing index links above go to sec.gov.